<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630018</url>
  </required_header>
  <id_info>
    <org_study_id>11AOC09J</org_study_id>
    <nct_id>NCT01630018</nct_id>
  </id_info>
  <brief_title>Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial</brief_title>
  <official_title>A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of belotecan or topotecan
      in patients with recurrent or refractory ovarian cancer (AOC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and
      Safety of Belotecan (CamtoBell inj.) or Topotecan in Patients with Recurrent or Refractory
      Ovarian Cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>approximately 21 days(every 1 Cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>up tp 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Topotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topotecan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Camtobell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Belotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression</description>
    <arm_group_label>Topotecan</arm_group_label>
    <other_name>Hycamtin inj.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belotecan</intervention_name>
    <description>0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression</description>
    <arm_group_label>Camtobell</arm_group_label>
    <other_name>Camtobell inj.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Histological or cytological diagnosis of AOC

          -  Stable disease (SD) or progression at time of study entry Recurrent or progressive AOC
             ≥ 90 days of duration of response for first-line therapy

          -  Measurable disease defined by RECIST criteria

          -  ECOG Performance Status of 0, 1, or 2

          -  Life expectancy &gt; 3 months

          -  Adequate bone marrow, Renal, Hepatic reserve:

               -  absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/μL

               -  platelet count ≥ 100,000 cells/μL

               -  hemoglobin ≥ 9 g/dL

               -  Total bilirubin ≤ 1.5 X ULN

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 X ULN

               -  Alkaline Phosphatase (ALP) ≤ 2.0 X ULN

               -  Serum creatinine &lt; 1.5mg/dL or calculated creatinine clearance &gt; 60mL/min

          -  Signed a written informed consent

        Exclusion Criteria:

          -  Active infection

          -  Symptomatic brain lesion

          -  Any other type of cancer during the previous 5 years except appropriately treated
             basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent
             diseases

          -  Prior anticancer therapy within 4 weeks before enroll

          -  Active pregnancy test and Pregnant or nursing women

          -  Participation in any investigational drug study within 28 days prior to study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Sang Song, phD, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Metropolitan</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Belotecan</keyword>
  <keyword>Topotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Belotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

